异基因造血干细胞移植后急性髓系白血病的维持治疗。
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
机构信息
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
出版信息
J Hematol Oncol. 2021 Jan 6;14(1):4. doi: 10.1186/s13045-020-01017-7.
Abstract
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.
摘要
在接受异基因造血干细胞移植（allo-HSCT）的急性髓系白血病（AML）患者中，复发仍然是治疗失败的主要原因。新出现的证据表明，AML 患者可能从移植后维持治疗中获益，特别是对于高危 AML 患者。在这个迷你综述中，我们将总结移植后作为 AML 患者维持治疗的靶向药物，如低甲基化剂、FLT3 抑制剂和异柠檬酸脱氢酶抑制剂。
相似文献
1
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后急性髓系白血病的维持治疗。
J Hematol Oncol. 2021 Jan 6;14(1):4. doi: 10.1186/s13045-020-01017-7.
2
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.索拉非尼作为 Fms 样酪氨酸激酶 3 突变型急性髓系白血病异基因造血干细胞移植后维持治疗药物的疗效和可行性：更新。
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.
3
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.索拉非尼对接受异基因造血干细胞移植的伴有 FLT3-ITD 急性髓系白血病患者结局的影响。
Cancer. 2018 May 1;124(9):1954-1963. doi: 10.1002/cncr.31295. Epub 2018 Mar 6.
4
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.FLT3-ITD阳性急性髓性白血病的异基因造血干细胞移植：移植后FLT3酪氨酸激酶抑制剂的作用
Biol Blood Marrow Transplant. 2016 Jun;22(6):982-990. doi: 10.1016/j.bbmt.2016.01.013. Epub 2016 Jan 16.
5
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).异基因造血干细胞移植治疗伴有内部串联重复突变的急性髓系白血病后的索拉非尼维持治疗（SORMAIN）。
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.
6
Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.急性髓系白血病异基因造血细胞移植后的药物维持策略。
Leuk Lymphoma. 2017 Mar;58(3):516-527. doi: 10.1080/10428194.2016.1205744. Epub 2016 Aug 11.
7
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.索拉非尼维持治疗在异基因造血细胞移植后的FLT3-ITD急性髓系白血病中似乎安全且能改善临床结局。
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
8
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.在异基因造血干细胞移植后复发的FLT3-ITD急性髓系白血病中，索拉非尼的血液学缓解率较高。
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.
9
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.低甲基化药物和 FLT3 抑制剂作为异基因造血干细胞移植后急性髓系白血病和骨髓增生异常综合征的维持治疗：系统评价和荟萃分析。
Transplant Cell Ther. 2021 Dec;27(12):997.e1-997.e11. doi: 10.1016/j.jtct.2021.09.005. Epub 2021 Sep 20.
10
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.索拉非尼作为Fms样酪氨酸激酶3突变型急性髓系白血病异基因造血干细胞移植后维持治疗药物的疗效及可行性
Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.
引用本文的文献
1
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.大剂量阿糖胞苷联合伊达比星巩固治疗首次完全缓解的急性髓系白血病：一项随机对照试验。
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655-x.
2
Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation.阿扎胞苷用于异基因造血干细胞移植后髓系恶性肿瘤患者的维持治疗。
Sci Rep. 2025 Apr 18;15(1):13402. doi: 10.1038/s41598-025-98059-z.
3
Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.维奈托克添加到CLAG方案中可能会改善复发/难治性急性髓系白血病患者的预后。
Ther Adv Hematol. 2025 Feb 10;16:20406207251319603. doi: 10.1177/20406207251319603. eCollection 2025.
4
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.基于地西他滨的治疗策略改善了 JMML 患者 HSCT 的预后：一项回顾性队列研究。
Front Immunol. 2024 Aug 26;15:1426640. doi: 10.3389/fimmu.2024.1426640. eCollection 2024.
5
Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.骨髓纤维化对急性髓系白血病异基因造血干细胞移植结局的影响。
Bone Marrow Transplant. 2024 Dec;59(12):1654-1666. doi: 10.1038/s41409-024-02402-3. Epub 2024 Aug 27.
6
WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients.WT1 基因突变影响 2 例伴中高危骨髓增生异常综合征患者的移植后复发。
Ann Hematol. 2024 Aug;103(8):2827-2836. doi: 10.1007/s00277-024-05870-1. Epub 2024 Jul 6.
7
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.组学在急性髓系白血病诊断、预后及治疗中的应用。
Biomark Res. 2024 Jun 10;12(1):60. doi: 10.1186/s40364-024-00600-1.
8
Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.ddPCR 技术在移植后早期进行的微小残留病监测可补充传统 MFC 方法，预测 AML/MDS 患者 HSCT 后复发：一项多中心回顾性研究。
J Transl Med. 2024 Apr 30;22(1):410. doi: 10.1186/s12967-024-05114-w.
9
[Clinical analysis of allogeneic hematopoietic stem cell transplantation for seven cases of acute myeloid leukemia with BCR::ABL1 fusion].7例BCR::ABL1融合的急性髓系白血病异基因造血干细胞移植的临床分析
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):995-1000. doi: 10.3760/cma.j.issn.0253-2727.2023.12.005.
10
Human Leukocyte Antigen-Haploidentical Haematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for Paediatric Haematological Malignancies.采用移植后环磷酰胺的人类白细胞抗原半相合造血干细胞移植治疗儿童血液系统恶性肿瘤
Cancers (Basel). 2024 Jan 31;16(3):600. doi: 10.3390/cancers16030600.
本文引用的文献
1
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.维奈托克作为高危复发 AML 患者移植后的维持治疗是安全耐受的。
Bone Marrow Transplant. 2023 Aug;58(8):849-854. doi: 10.1038/s41409-023-01987-5. Epub 2023 Apr 25.
2
Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study.FLT3突变型急性髓系白血病的异基因干细胞移植：T细胞清除和移植后索拉非尼维持治疗可改善生存率。一项急性白血病工作组-欧洲血液和骨髓移植学会的回顾性研究。
Clin Hematol Int. 2019 Mar 18;1(1):58-74. doi: 10.2991/chi.d.190310.001. eCollection 2019 Mar.
3
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.FLT3 治疗靶点及其在急性髓系白血病中的相关耐药性。
J Hematol Oncol. 2020 Nov 19;13(1):155. doi: 10.1186/s13045-020-00992-1.
4
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.rhG-CSF 联合地西他滨预防高危 MRD 阴性 AML 患者 HSCT 后复发的疗效：一项开放标签、多中心、随机对照试验。
J Clin Oncol. 2020 Dec 20;38(36):4249-4259. doi: 10.1200/JCO.19.03277. Epub 2020 Oct 27.
5
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.伴有 FLT3 抑制剂的序贯治疗在 AML 患者中的疗效。
J Hematol Oncol. 2020 Oct 8;13(1):132. doi: 10.1186/s13045-020-00964-5.
6
Sorafenib prevents AML relapse after allo-HSCT.索拉非尼可预防异基因造血干细胞移植后急性髓系白血病复发。
Nat Rev Clin Oncol. 2020 Oct;17(10):591. doi: 10.1038/s41571-020-00431-7.
7
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.索拉非尼维持治疗伴 FLT3-ITD 急性髓系白血病行异基因造血干细胞移植患者：一项开放标签、多中心、随机 3 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10.
8
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
9
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.老年急性髓系白血病化疗与 Venetoclax 试验（CAVEAT）：Venetoclax 联合改良强化化疗的 1b 期剂量递增研究。
J Clin Oncol. 2020 Oct 20;38(30):3506-3517. doi: 10.1200/JCO.20.00572. Epub 2020 Jul 20.
10
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).异基因造血干细胞移植治疗伴有内部串联重复突变的急性髓系白血病后的索拉非尼维持治疗（SORMAIN）。
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.
Zotero 插件